This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Christian Tesche (Division of CardiovascularImaging, Department of Radiology and Radiological Science, Medical University of South Carolina and Department of Cardiology, Munich University Clinic, Ludwig-Maximilian-University).
25, 2024 in the European Heart Journal CardiovascularImaging. 25, 2024 in the European Heart Journal CardiovascularImaging 1. 25, 2024 in the European Heart Journal CardiovascularImaging 1. Presented at the European Association of CardiovascularImaging: Late Breaking Clinical Research and Trials.
Cardiovascular AI maintains a (distant) second largest share of FDA-cleared AI products, with 10% of total clearances (90), well below radiology’s 76% share (671). Cardiovascular AI actually makes up a larger 17.4% FFRCT, coronary plaque, etc). in 2020-2022, and 13.5% since the start of 2023.
This funding will allow us to expand our commercial reach, which is especially germane following our recent achievements in attaining Medicare coverage and a CPT Category I code for advanced plaque analysis. Barclay continued, “Cardiovascular disease is the #1 cause of death globally and costs our country $422B annually.
However, cardiovascular AI actually made up a larger 18% share of total H1 2024 clearances (19 devices) if you also count cardiovascularimaging AI products that the FDA technically categorized within its “Radiology” segment (e.g.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content